Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05704985 · ClinicalTrials.gov registry record · Phase 1
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
A Phase 1 study of Cancer and Non-Small Cell Lung Cancer, sponsored by DEKA Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 7
- Study locations
NCT05704985: Active Phase 1 study of Cancer and Non-Small Cell Lung Cancer, sponsored by DEKA Biosciences.
NCT05704985 is a Phase 1 study of Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by DEKA Biosciences. The registered enrollment target is 39 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05704985, a Phase 1 study of Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by DEKA Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
Primary Outcome
Based on toxicities observed
Conditions Studied
Interventions
- DRUG Chemotherapy
- RADIATION Radiation therapy
- BIOLOGICAL DK210 (EGFR)
- BIOLOGICAL Immune checkpoint blockers
Study Locations (7)
Texas
- Mary Crowley Cancer Research - Dallas
- University of Texas Southwestern - Dallas
- The University of Texas M.D. Anderson Cancer Center - Houston
California
- City of Hope - Duarte
New York
- Northwell Health - Manhasset
Oklahoma
- OU Health Stephenson Cancer Center - Oklahoma City
Virginia
- NEXT Oncology - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2025-10 |
| Phase | Phase 1 |
What the registry record for NCT05704985 still lists
NCT05704985 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 9 conditions, with Cancer appearing as the primary indexed condition, and to 4 interventions - of which Chemotherapy is the first listed.
NCT05704985 lists 7 locations in 5 states (Texas, California, New York).
Frequently Asked Questions
What is clinical trial NCT05704985 about?
NCT05704985 is a clinical study titled "Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors". This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
What is the current status of trial NCT05704985?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2023-04-03. Estimated completion is 2025-10.
What conditions does trial NCT05704985 study?
This clinical trial studies the following conditions: Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Cancer, Solid Tumor.
What interventions are being tested in trial NCT05704985?
The interventions under investigation include: Chemotherapy (DRUG), Radiation therapy (RADIATION), DK210 (EGFR) (BIOLOGICAL), Immune checkpoint blockers (BIOLOGICAL).
Who is sponsoring clinical trial NCT05704985?
This trial is sponsored by DEKA Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05704985 being conducted?
This trial has 7 study locations across California, New York, Oklahoma, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05704985's enrollment target sits among peer trials
39 471st of 615 higher than 141 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI